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Teaching Lecture: Brachytherapy for the pelvic region: 
status and perspective for the future  
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Brachytherapy in gynaecological cancers, and especially in 
cervix cancer, has greatly evolved during the last twenty 
years. For decades, brachytherapy has relied on x-ray 
orthogonal acquisitions, and prescription has been a matter 
of systems and schools, making reporting and comparisons 
difficult. Based on the developments of afterloaders and 
treatment planning systems, image-guided adaptive 
brachytherapy has emerged. This high precision technique 
combines all modern radiation requirements: image 
guidance, adaptation to tumor response, and short time 
treatment.  
Ten years ago, the GEC-ESTRO, in a will of harmonizing 
practices, published recommendations in cervical cancers 
regarding the definition of target-volumes and the reporting. 
These recommendations were rapidly adopted worldwide. 
During the last decade, multiple monocentric series, 
historical cohorts’ comparisons, and a prospective 
multicentric study (STIC trial) demonstrated high local 
control rates with a limited morbidity in regard to classical 
data. These data are about to be confirmed by two large 
studies led by the Gyn GEC-ESTRO: Retro-EMBRACE and 
EMBRACE, which will establish MRI-guided brachytherapy as a 
gold standard.  
In addition, clear dose-volume effect relationships have been 
demonstrated between the modern dosimetric parameters 
and the probability of achieving local control or facing 
morbidity. The better knowledge of these correlations 
allowed the launch of EMBRACE II, a prospective study 
combing the best radiation modalities (EBRT and IGABT), 
with optimal and ambitious planning aims. In the near future, 
the large amount of data collected in the EMBRACE study (> 1 
500 patients accrued) will allow the development of 
monograms integrating not only dosimetric parameters, but 
also criteria on comorbidities, clinical features, and tumor 
response to external beam radiotherapy. This would be of 
great help in adapting and personalizing treatment plans.  
Longer-term prospects include the development of 
alternative image modalities for guidance, such as endorectal 
ultrasound, cheaper and more accessible than MRI, or 
conversely, a more advanced and sophisticated image 
modality.  
Image-guided brachytherapy is also progressively declined in 
other gynecologic tumors, such as vagina cancer or non-
operable endometrial cancer. 
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Prostate brachytherapy allows radiation dose escalation 
directly into the gland with minimal dose to adjacent rectum 
and bladder. Over the last decade improvements in 
brachytherapy technology have refined dose delivery with 
the introduction of HDR after loading devices, more 
sophisticated treatment planning systems and the 
incorporation of functional imaging into the planning process. 
This teaching lecture will provide an overview of the 
techniques, indications, and clinical outcomes for both 
permanent and High Dose Rate prostate brachytherapy. 
Recent results from randomised clinical trials will be 
critiqued and emerging indications including focal and 
salvage treatments discussed. 
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for coping with anatomical variations: hope or hype?  
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Introduction: Variation in shape, position and treatment 
response of both tumour and organs at risk are major 
challenges for accurate dose delivery in radiotherapy. 
Adaptive radiotherapy (ART) has been proposed to customise 
the treatment to these motion/response patterns of the 
individual patients, but increases workload thus challenge 
clinical implementation. This presentation presents a review 
of the clinically implemented ART in addition to in silico 
workflows that have been published on pelvic tumours.  
 
Material and methods: Initial identification of papers was 
based on searches in PubMed. For each tumour site (prostate, 
gynaecological [gynae], bladder, ano-rectal), the identified 
papers were screened independently by two researches for 
selection of studies describing all processes of an ART 
workflow: treatment monitoring and evaluation, decision and 
execution of adaptations. Both brachytherapy (BT) and 
external beam studies were eligible in the review.  
 
Result: The review consisted of 43 clinical studies and 51 in 
silico studies. For prostate, 1219 patients were treated with 
offline re-planning workflows, mainly to adapt prostate 
motion relative to bony anatomy. For gynae 1155 patients 
were treated with online BT re-planning while 25 ano-rectal 
cancer patients were treated with offline re-planning, all to 
account for tumour regression detected by MRI/CT. For 
bladder and gynae, 161 and 64 patients respectively, were 
treated with library-based online plan selection to account 
for target volume and shape variations (Figure). In 
comparison to non-ART, sparing of rectum (prostate and 
bladder cancer), bladder (ano-rectal cancer) and bowel 
cavity (gynae and bladder cancer) was reported with ART. 
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Conclusion: Implementations of ART were dominated by 
offline re-planning and online BT re-planning, although 
recently online plan selection workflows have increased with 
the availability of cone-beam-CT. Advantageous dosimetric 
and outcome related patterns using ART was documented by 
the studies included the review. Despite this, clinical 
implementations have been scarce, especially regarding 
prostate and the vast amount of in silico studies available. 
Identified challenges, hindering successful clinical 
implementations, were re-contouring of target/OARs in 
addition to patient selection, aiding the focus of the 
adaptations to the more challenging patients.  
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Currently, with our highly conformal modulated radiotherapy 
techniques, we are capable of delivering high radiation doses 
to tumour volumes, whilst minimizing dose to the surrounding 
structures. However, today’s radiotherapy is based on the 
dogmatic concept of unchanging anatomy of tumors, 
surrounding normal organs and tissues, where radiotherapy 
plans solely based on pre-treatment imaging are delivered 
invariably for several weeks of treatment. Conversely, during 
a course of curative radiotherapy, tumors and to some 
extend OARs change. In the field of head and neck cancer, 
tumor and lymph nodes shrink up to 3% per day, changing 
size, shape and position. External contour modifications 
result from loss of weight and muscle mass, altering the 
geometry of the disease in relation to OARs. This leads to 
changes in the anatomy of patients, impacting the dose 
distribution that may differ significantly from what was 
planned. In this context, considerable efforts have been put 
on adaptive radiotherapy (ART), i.e. to adapt the treatment 
delivery on the basis of changes in the tumor and/or normal 
tissues during the course of radiotherapy. The aim is then to 
compensate for under-dosage of the target volumes or over-
dosage of OARs.  
Re-imaging and re-planning evidently result in an extra 
workload and cost. Therefore, although ART is an appealing 
concept, it is at present not used on a routine basis for all 
patients. The optimal implementation strategy regarding 
selection of patients and timing of imaging/replanning 
remains to be defined. Several groups are currently 
investigating these questions, and an overview of the results, 
from a physician’s perspective will be presented. 
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Adaptive radiotherapy is an emerging area of radiotherapy. In 
general there are two categories of adaptive radiotherapy 
leading to either pro-active or reactive adaptations. As the 
terms suggest, pro-active adaptation is chosen in advance of 
the patient commencing treatment, whereas reactive 
adaptation is unscheduled and arises from an unexpected 
patient change seen during treatment.  
There are 3 distinct categories for which adaptive 
radiotherapy approaches should be considered. The 
categories and most appropriate form of adaptation are given 
in table 1.  
 
Table 1. 
Patient 
Characteristic 
Example 
clinical 
site 
Type of 
Adaptation 
Most likely 
Adaptive 
approach 
Frequency 
of 
adaptation 
Daily anatomy 
change  
Bladder Pro-active 
adaptation 
Based on 
small 
number of 
pre-
determined 
options 
Daily  
Slowly 
changing 
anatomy over 
treatment 
course 
Head & 
Neck 
Pro-active 
adaptation 
Modified 
treatment 
plan based 
on new 
patient 
anatomy 
information 
≤ Weekly 
Unexpected 
anatomy 
changes 
Any Reactive 
adaptation 
Modified 
treatment 
plan based 
on new 
patient 
anatomy 
information 
Unscheduled 
 
Studies of safety in radiotherapy have shown that there is a 
higher risk of deviation during handoffs between staff groups 
with tight coupling and when decisions are made under 
significant time pressure. Deviation rates of <0.5% per 
fraction have been reported1-4, leading to deviation rates in 
the range 1-2% per patient. Adaptive radiotherapy can be 
seen as increasing the complexity of handoffs and creating 
more frequent decision making points in the process under 
time pressure. In this context the introduction of adaptive 
radiotherapy needs to be made whilst mitigating the risk of 
significantly increasing deviation rates. .  
Justification is required for adaptation from the assessment 
of risks and benefits from adaptive approaches. As there is 
currently no clear clinical benefit from adaptive 
radiotherapy, new risks need to be mitigated to ensure there 
is an overall patient benefit. Once procedures have been 
developed for an adaptive approach, changes in personnel, 
training and workload are likely to be needed to ensure the 
safe use of adaptive radiotherapy. For example, there are 
significant training requirements for radiotherapy treatment 
staff when applying pro-active adaptive radiotherapy 
techniques where the most appropriate plan must be chosen 
at each treatment fraction.  
Reactive adaptation has organically arisen from the routine 
use of online image-guidance. For example using cone-beam 
CT has provided a wealth of information regarding patient 
anatomy changes during the course of radiotherapy. 
Inevitably changes in patient anatomy seen during treatment 
lead to questions regarding the appropriateness of the 
original treatment plan. It is likely that around 20% of 
patients receiving radiotherapy will have anatomy changes 
requiring assessment for appropriateness of their original 
treatment plan during the course of their treatment. 
However, modifications to treatments should only be enacted 
if the patient benefit from the change outweighs the risk of a 
deviation that could lead to worse patient outcome. Applying 
this approach is likely to lead to <5% of patients requiring a 
modification to their treatment. Therefore, at the very least, 
departments will require efficient processes for the review of 
treatment plans against changes to patient anatomy.  
In conclusion, currently the clinical justification for adaptive 
radiotherapy approaches is unclear but the adoption rate is 
likely to continue to rise due to the available technology. In 
this context there is a requirement to ensure staffing, 
